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We developed a reproducible model of neutrophilic
inflammation in cynomolgus monkeys (Macaca fascicu-
laris) in order to study potential novel anti-inflammatory
compounds intended for respiratory diseases such as
COPD and asthma. Using a pediatric bronchoscope, a
baseline bronchoalveolar lavage (BAL) was performed on
the left lung prior to LPS segmental challenge to the right
lung. At 24, 72 and 168 hours post challenge, BAL fluid
(BALF) was collected to assess the level of pulmonary
inflammation. At both 24 and 72 hours (Hr) post LPS
challenge, total BAL cells were significantly elevated over
baseline. BAL cell differentials revealed that mean percent
neutrophils significantly increased from baseline (1.3
±1.6%) to (74.0 ± 21.9% at 24 Hr and 26.6 ± 21.0% at
72 Hr) whereas, BAL macrophage numbers had signifi-
cantly decreased from baseline (94.4 ± 3.1%) to (31.6 ±
21.2 % at 24 Hr and 64.2 ± 20.1% at 72 Hr) post challenge.
In addition to increased inflammation, we also observed a
significant increase in BAL cell gene expression of MMP-9
and significant increases in sCD14 and IL-8 from concen-
trated BALF 24 Hr post challenge. Numbers of infiltrating
cells and other inflammatory parameters returned to base-
line levels by 168 Hr following LPS challenge. In some stu-
dies, intramuscular injections of dexamethasone (Dex
[1 mg/kg]) were administered 24 Hr prior and just prior
to LPS challenge. Dex did not significantly reduce total
BAL inflammation or IL-8 protein, but did significantly
reduce percent neutrophils and sCD14 protein within the
BALF 24 hours post challenge. Dex also significantly
increased percent macrophages 24 Hr post challenge.
These data show that segmental challenge with LPS pro-
duces an acute pulmonary neutrophilic inflammation,
which is reduced by pretreatment with Dex. This reprodu-
cible, short-term, large animal model may help us to better
understand neutrophillic inflammation pathways contri-
buting to lung injury and host defense.
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